Target Validation Information
TTD ID T76846
Target Name Melanocortin receptor 3 (MC3R)
Type of Target
Literature-reported
Drug Potency against Target Melanotetan II Drug Info IC50 = 0.57 nM [9]
Ac-dR[CEHdFRWC]-NH2 Drug Info Ki = 56.79 nM [2]
Ac-His-D-Phe-Arg-2-Nal-NHCH3 Drug Info Ki = 1195 nM [6]
Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 Drug Info IC50 = 2.3 nM [8]
Ac-R[CEHdFRWC]-NH2 Drug Info Ki = 33.76 nM [2]
Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 Drug Info Ki = 1727 nM [6]
Ac-YCit[CEHdFRWC]-NH2 Drug Info Ki = 313.48 nM [2]
Ac-YK[CEHdFRWC]-NH2 Drug Info Ki = 97.97 nM [2]
Ac-YRC(Me)*EHdFRWC(Me)NH2 Drug Info Ki = 166.41 nM [2]
Ac-YRMEHdFRWG-NH2 Drug Info Ki = 1.44 nM [2]
Ac-YRMEHdFRWGSPPKD-NH2 Drug Info Ki = 0.11 nM [2]
Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 Drug Info Ki = 6.84 nM [2]
Ac-YR[CEH(pCl-dF)RWC]-NH2 Drug Info Ki = 3.12 nM [2]
Ac-YR[CEH(pF-dF)RWC]-NH2 Drug Info Ki = 15.87 nM [2]
Ac-YR[CEHdFRWC]-NH2 Drug Info Ki = 55.02 nM [2]
Ac-YR[CEHdFRWC]SPPKD-NH2 Drug Info Ki = 7.91 nM [2]
Ac-[CEHdFRWC]-NH2 Drug Info Ki = 399.7 nM [2]
AEKKDEGPYRMEHFRWGSPPKD Drug Info Ki = 10.64 nM [2]
Afamelanotide Drug Info IC50 = 19 nM [3]
C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 Drug Info IC50 = 12 nM [7]
C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 Drug Info IC50 = 84 nM [7]
C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Drug Info IC50 = 11 nM [7]
C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 Drug Info IC50 = 385 nM [7]
C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 Drug Info IC50 = 23 nM [7]
C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2 Drug Info IC50 = 1100 nM [7]
C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 Drug Info IC50 = 32 nM [7]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 2.6 nM [5]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 140 nM [5]
C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 820 nM [5]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 1.4 nM [5]
C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 270 nM [5]
C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 140 nM [5]
C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 1200 nM [5]
C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 12 nM [5]
C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 560 nM [5]
C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 6 nM [5]
C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 250 nM [5]
C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 13 nM [5]
C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 2700 nM [5]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 Drug Info IC50 = 1.7 nM [5]
C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 Drug Info IC50 = 600 nM [5]
GPYRMEHFRWGSPPKD-NH2 Drug Info Ki = 9.23 nM [2]
MK-10 Drug Info Ki = 390 nM [1]
MK-11 Drug Info Ki = 140 nM [1]
MK-9 Drug Info Ki = 5.9 nM [7]
MT-II Drug Info IC50 = 1.3 nM [8]
NDP-SYSMEHFRWGKPVG Drug Info Ki = 0.23 nM [2]
Tic-D-Phe-Arg-2-Nal-NHCH3 Drug Info Ki = 1632 nM [4]
References
REF 1 Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
REF 2 Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
REF 3 Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxo... Bioorg Med Chem Lett. 2005 Aug 1;15(15):3501-5.
REF 4 Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.
REF 5 Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
REF 6 Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
REF 7 Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
REF 8 Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
REF 9 Metabolic fate of endogenously synthesized prostaglandin D2 in a human female with mastocytosis. Prostaglandins. 1985 Sep;30(3):383-400.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.